OR1D2: A Potential Drug Target and Biomarker (G4991)
OR1D2: A Potential Drug Target and Biomarker
OR1D2, short for OLlan dimer, is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. OR1D2 is a member of the superfamily of G-coupled proteins, which includes proteins involved in a variety of cellular processes, including signaling, cytoskementation, and chromatin remodeling.
Recent studies have identified OR1D2 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. This is due to the fact that OR1D2 has been shown to play important roles in several cellular processes that are involved in disease development, such as cell signaling, angiogenesis, and inflammation.
One of the key functions of OR1D2 is its role in cell signaling. OR1D2 is a negative regulator of the TGF-β pathway, which is involved in cell signaling and growth. This means that when TGF-β signaling is activated, OR1D2 is inhibited, and when TGF-β signaling is inhibited, OR1D2 is activated. This regulation is important for maintaining tissue homeostasis and for preventing cancer progression.
In addition to its role in cell signaling, OR1D2 has also been shown to be involved in the regulation of angiogenesis, the process by which new blood vessels are formed. OR1D2 has been shown to play a key role in the production of sprout angioms, which are small blood vessels that form during the development of new blood vessels. This is important for the formation of new blood vessels, which is a critical component of cancer growth and progression.
OR1D2 has also been shown to be involved in the regulation of inflammation. OR1D2 is a nuclear factor kappa B (NFKB) inhibitor, which means that it inhibits the activity of the NFKB signaling pathway. This is important for the regulation of inflammation, as the NFKB pathway is involved in the production of pro-inflammatory cytokines that contribute to inflammation.
Despite its involvement in several important cellular processes, OR1D2 is not yet a well-established drug target or biomarker. There are currently no FDA-approved drugs that are specifically targeted at OR1D2. However, this is an area of 鈥嬧?媋ctive research, and scientists are working to identify new drug targets and biomarkers for OR1D2.
One approach to identifying new drug targets for OR1D2 is to use a combination of techniques, including high-throughput screening and gene expression analysis. This approach has been used to identify several potential drug targets for OR1D2, including those involved in cell signaling, angiogenesis, and inflammation.
In addition to its potential drug targets, OR1D2 also has the potential to serve as a biomarker for several diseases. For example, OR1D2 has been shown to be involved in the regulation of angiogenesis, which is an important predictor of cancer outcomes. This suggests that OR1D2 may be a useful biomarker for cancer diagnosis and treatment.
OR1D2 has also been shown to be involved in the regulation of inflammation, which is a key predictor of cardiovascular disease. This suggests that OR1D2 may be a useful biomarker for cardiovascular disease diagnosis and treatment.
In conclusion, OR1D2 is a protein that is involved in several important cellular processes, including cell signaling, angiogenesis, and inflammation. As a result, OR1D2 has the potential to serve as a drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Further research is needed to fully understand the role of OR1D2 in these processes and to identify new drug targets and biomarkers for this protein.
Protein Name: Olfactory Receptor Family 1 Subfamily D Member 2
Functions: Odorant receptor which may be involved in sperm chemotaxis. Bourgeonal is a strong chemoattractant for sperm in vitro and is shown to be a strong agonist for OR1D2 in vitro. May also function in olfactory reception
The "OR1D2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR1D2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR1D4 | OR1D5 | OR1E1 | OR1E2 | OR1E3 | OR1F1 | OR1F2P | OR1G1 | OR1I1 | OR1J1 | OR1J2 | OR1J4 | OR1K1 | OR1L1 | OR1L3 | OR1L4 | OR1L6 | OR1L8 | OR1M1 | OR1N1 | OR1N2 | OR1P1 | OR1Q1 | OR1S1 | OR1S2 | OR2A1 | OR2A1-AS1 | OR2A12 | OR2A14 | OR2A2 | OR2A20P | OR2A25 | OR2A4 | OR2A42 | OR2A7 | OR2A9P | OR2AE1 | OR2AG1 | OR2AG2 | OR2AJ1 | OR2AK2 | OR2AL1P | OR2AM1P | OR2AP1 | OR2AT4 | OR2B11 | OR2B2 | OR2B3 | OR2B6 | OR2C1 | OR2C3 | OR2D2 | OR2D3 | OR2F1 | OR2F2 | OR2G2 | OR2G3 | OR2G6 | OR2H1 | OR2H2 | OR2I1P | OR2J1 | OR2J2 | OR2J3 | OR2J4P | OR2K2 | OR2L13 | OR2L1P | OR2L2 | OR2L3 | OR2L5 | OR2L8 | OR2L9P | OR2M1P | OR2M2 | OR2M3 | OR2M4 | OR2M5 | OR2M7 | OR2Q1P | OR2S2 | OR2T1 | OR2T10 | OR2T11 | OR2T12 | OR2T2 | OR2T27 | OR2T29 | OR2T3 | OR2T33 | OR2T34 | OR2T35 | OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2
